ERCC2 and cancer: In other words, if HR + NHEJ pathways are inactivated by SFN analogs, the compensatory NER pathway requiring ERCC2 would be further compromised due to bromodomain inhibition, leading to a cellular crisis in cancer cells (Figure S6), unlike in normal colonic epithelial cells that are less susceptible to the drug treatments (Figure S3).